News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diatos S.A. Announces Start of the Preclinical Toxicology Program of DTS-108, a Second Generation Irinotecan


10/17/2007 1:20:38 PM

Paris, France, 17 October 2007 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced today the start of its regulatory toxicology program of DTS-108, with a Phase I trial planned in the first half of 2008. DTS-108 is a Vectocell® based prodrug of SN38, the active metabolite of irinotecan that is currently used for the treatment of colon and lung cancer.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES